Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
UCBCares: Providing Dedicated Patient Support
Clinical studies at UCB: How are medicines made and tested?
Twitter Feed
-
Yesterday, the German UCB team sponsored a successful symposium about psoriasis therapy at digital congress #FOBIDIGITAL, always striving to increase the lives of patients living with psoriasis. Find out more about psoriasis here (German): https://t.co/ov
— UCB News (@ucb_news) 10.07.2020 -
The objective of the UCB Community Health Fund is to positively impact the health of vulnerable people. We will address relevant needs that are likely to evolve over time and will be dependent on local contexts. Find out more in our infographic: https://t
— UCB News (@ucb_news) 10.07.2020 -
We officially welcome our new EVP and Chief Financial Officer Sandrine Dufour https://t.co/epocbiCUqH
— UCB News (@ucb_news) 08.07.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
